XERS — Xeris Biopharma Holdings, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1867096 ·
Last close
$16.80
Market Cap
$3.07B
52W High
$16.98
52W Low
$5.25
ADV30
3,065,584
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 92,100,000 79,588,000 5,173,000 -31,101,000 411,905,000 121,747,000 421,639,000
Mar 2026 83,127,000 72,553,000 7,916,000 2,234,000 392,013,000 111,750,000 379,002,000
Dec 2025 85,807,000 74,860,000 16,773,000 11,081,000 383,527,000 111,042,000 369,838,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$56,608,000
Investing CF
$-938,000
Financing CF
$6,690,000
CapEx
$-938,000
Dividends Paid
—
Buybacks
$-19,226,000
EPS Diluted TTM
$-0.05
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-700,174,000
Inventory
$80,930,000
Receivables
$58,105,000
ST Investments
—
EBIT TTM
$11,087,000
Pretax Income TTM
$-17,165,000
Interest Exp TTM
$28,252,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$368,259,008
EBITDA
$58,929,000
Free Cash Flow
$52,450,124
Enterprise Value
$2,872,024,576
Total Cash
$131,082,000
Total Debt
$226,066,000
Shares Out
182,700,038
Trailing EPS
$-0.03
Book Value
$0.27
ROE
-27.1%
ROA
7.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 291,845,000 24,896,000 554,000 383,527,000 369,838,000 13,689,000 28,626,000
Dec 2024 203,070,000 -33,646,000 -54,836,000 323,060,000 352,675,000 -29,615,000 -36,981,000
Dec 2023 163,914,000 -44,010,000 -62,255,000 322,602,000 329,384,000 -6,782,000 -47,023,000
Dec 2022 110,248,000 -81,940,000 -94,660,000 344,522,000 299,335,000 45,187,000 -102,891,000

TTM Snapshot

Revenues TTM
$335,414,000
NetIncome TTM
$-17,165,000
OpCashFlow TTM
—
Assets (Latest)
$411,905,000
Forward EPS
$0.27

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $11.00 · spot: $16.99 · call volume: 4,244 · put volume: 11
Expected Move to 2027-01-15: ±$5.03 (29.61%) — implied range $11.96 – $22.02 · ATM straddle on $17.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
BGM BGM Group Ltd. $3.09B $8.13 —
TLX Telix Pharmaceuticals Ltd $3.01B $8.85 —
LEGN Legend Biotech Corp $3.13B $16.11 —
DYN Dyne Therapeutics, Inc. $3.00B $16.02 —
ACAD ACADIA PHARMACEUTICALS INC $3.17B $18.32 —

News headlines (Yahoo Finance, 1h cache)

Xeris Biopharma Holdings (XERS) Stock May Be Worth More Following Raised Revenue Guidance
2026-11-18 02:18 · Yahoo
XERS, CARL Stocks Hit All-Time Highs Today – Here’s What Analysts Are Saying
2026-11-11 18:23 · Yahoo
Is Xeris Biopharma Holdings (XERS) Overpriced After Its Q3 Beat And 2026 Outlook Raise?
2026-11-07 18:13 · Yahoo
Xeris Biopharma (XERS) Adds Menassie M. Taddese To Its Board
2026-11-07 11:13 · Yahoo
Xeris Biopharma Q3 Earnings Call Highlights
2026-11-06 23:14 · Yahoo
Xeris Biopharma Holdings Inc (XERS) (Q3 2026) Earnings Call Highlights: Revenue Surges 44% as ...
2026-11-06 21:08 · Yahoo
Xeris Biopharma Holdings, Inc. Q3 2026 Earnings Call Summary
2026-11-05 22:47 · Yahoo
Xeris Biopharma (XERS) Q3 2026 Earnings Call Transcript
2026-11-05 21:34 · Yahoo
Xeris CEO Sees Recorlev Nearing $1B In Annual Sales 3 To 4 Years Earlier Than Expected – XERS Stock On Track To Hit Over 7-Year Highs
2026-11-05 13:55 · Yahoo
Xeris Biopharma (XERS) Surpasses Q3 Earnings and Revenue Estimates
2026-11-05 13:35 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.